Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM31YGM)

Drug Name
Monoctanoin component C Drug Info
Synonyms
DICAPRYLIN; MONOCTANOIN COMPONENT C; 1069-87-0; 3-Hydroxypropane-1,2-diyl dioctanoate; 36354-80-0; diC8; Octanoic acid, 1-(hydroxymethyl)-1,2-ethanediyl ester; 1,2-Dicapryloylglycerol; 1,2-Dioctanoyl-rac-glycerol; 1,2-Dioctanoin; Octanoin, 1,2-di-; Glycerol 1,2-dicaprylate; AC1Q5YA4; SCHEMBL825310; CHEMBL24609; AC1L1B82; CTK4A4899; ZQBULZYTDGUSSK-UHFFFAOYSA-N; HSCI1_000084; IN1353; AKOS027383004; ACM36354800; (3-hydroxy-2-octanoyloxypropyl) octanoate; FT-0748382; 1-hydroxy-3-(octanoyloxy)propan-2-yl octa
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
1323
CAS Number
CAS 1069-87-0
TTD Drug ID
DM31YGM

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Discontinued Drug(s)
Investigative Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Protein kinase C gamma (PRKCG)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Midostaurin DMI6E0R Acute myeloid leukaemia 2A60 Approved [2]
BALANOL DMDLN9E N. A. N. A. Terminated [3]
RO-320432 DMFZ1YW N. A. N. A. Terminated [4]
LY-317644 DMM20PI N. A. N. A. Terminated [5]
RO-316233 DMAGLPW Discovery agent N.A. Investigative [6]
Bisindolylmaleimide-I DMOQJZC Discovery agent N.A. Investigative [7]
3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione DMDO175 Discovery agent N.A. Investigative [8]
3,4-diphenyl-1H-pyrrole-2,5-dione DMPK6YT Discovery agent N.A. Investigative [8]
3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione DMGC7RY Discovery agent N.A. Investigative [8]
3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione DM3EV9N Discovery agent N.A. Investigative [8]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Protein kinase C gamma (PRKCG) TTRFOXJ KPCG_HUMAN Inhibitor [1]

References

1 Synthesis and characterization of the second cysteine-rich region of mouse skin PKCGh, Bioorg. Med. Chem. Lett. 6(4):353-356 (1996).
2 A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
3 Evaluation of differential hypoxic cytotoxicity and electrochemical studies of nitro 5-deazaflavins, Bioorg. Med. Chem. Lett. 5(18):2155-2160 (1995).
4 Bisindolylmaleimide inhibitors of protein kinase C. Further conformational restriction of a tertiary amine side chain, Bioorg. Med. Chem. Lett. 4(11):1303-1308 (1994).
5 Synthesis of bisindolylmaleimide macrocycles, Bioorg. Med. Chem. Lett. 5(18):2093-2096 (1995).
6 Inhibitors of protein kinase C. 1. 2,3-Bisarylmaleimides. J Med Chem. 1992 Jan;35(1):177-84.
7 Protein kinase C epsilon regulates gamma-aminobutyrate type A receptor sensitivity to ethanol and benzodiazepines through phosphorylation of gamma2... J Biol Chem. 2007 Nov 9;282(45):33052-63.
8 Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. J Med Chem. 2006 Feb 23;49(4):1271-81.